Elaine E L Wang
Overview
Explore the profile of Elaine E L Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, et al.
Infect Dis Ther
. 2024 Aug;
13(10):2209-2210.
PMID: 39212853
No abstract available.
2.
Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, et al.
Infect Dis Ther
. 2024 Jun;
13(10):2105-2121.
PMID: 38941068
Introduction: Recurrent Clostridioides difficile infection (rCDI) often occurs after standard-of-care antibiotics. VOWST oral spores (VOS, previously SER-109), an FDA-approved orally administered microbiome therapeutic, is indicated to prevent rCDI following antibiotics...
3.
Berenson C, Lashner B, Korman L, Hohmann E, Deshpande A, Louie T, et al.
Clin Infect Dis
. 2023 Aug;
77(11):1504-1510.
PMID: 37539715
Background: Although comorbidities are risk factors for recurrent Clostridioides difficile infection (rCDI), many clinical trials exclude patients with medical conditions such as malignancy or immunosuppression. In a phase 3, double-blind,...
4.
Sims M, Khanna S, Feuerstadt P, Louie T, Kelly C, Huang E, et al.
JAMA Netw Open
. 2023 Feb;
6(2):e2255758.
PMID: 36780159
Importance: A safe and effective treatment for recurrent Clostridioides difficile infection (CDI) is urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted microbiome, which promotes spore germination...
5.
Cohen S, Louie T, Sims M, Wang E, Memisoglu A, McGovern B, et al.
JAMA
. 2022 Oct;
328(20):2062-2064.
PMID: 36260754
No abstract available.
6.
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Infection (rCDI)
Khanna S, Sims M, Louie T, Fischer M, LaPlante K, Allegretti J, et al.
Antibiotics (Basel)
. 2022 Sep;
11(9).
PMID: 36140013
Clostridioides difficile infection (CDI) is classified as an urgent health threat by the Centers for Disease Control and Prevention (CDC), and affects nearly 500,000 Americans annually. Approximately 20−25% of patients...
7.
Feuerstadt P, Louie T, Lashner B, Wang E, Diao L, Bryant J, et al.
N Engl J Med
. 2022 Jan;
386(3):220-229.
PMID: 35045228
Background: Current therapies for recurrent infection do not address the disrupted microbiome, which supports spore germination into toxin-producing bacteria. SER-109 is an investigational microbiome therapeutic composed of purified Firmicutes spores...
8.
Krueger J, Ferris L, Menter A, Wagner F, White A, Visvanathan S, et al.
J Allergy Clin Immunol
. 2015 Mar;
136(1):116-124.e7.
PMID: 25769911
Background: IL-23 is associated with plaque psoriasis susceptibility and pathogenesis. BI 655066 is a fully human IgG1 mAb specific for the IL-23 p19 subunit. Objective: This first-in-human proof-of-concept study evaluated...
9.
Shaikh N, Wang E, Arguedas A, Dagan R, Soley C, Song J, et al.
Pediatr Infect Dis J
. 2011 Jan;
30(3):253-5.
PMID: 21217538
We followed symptoms of children with acute otitis media (AOM), who were enrolled in a clinical trial that included a baseline tympanocentesis. We observed marked and rapid improvement in symptom...
10.
Wright J, Wang E, Owen J, Stephens D, Graham H, Hanlon M, et al.
Lancet
. 2005 Mar;
365(9465):1153-8.
PMID: 15794970
Background: Treatments for femoral fractures in children vary widely and have been investigated only in case series. We did a multicentre randomised trial to compare malunion rates after external fixation...